Hossam Abdulkhalek, Divisional Clinical Director of Cancer and Clinical services at Western Health and Social Care Trust, shared a post on LinkedIn:
” The first two days of ASCO 2026 have delivered some truly impactful updates across breast and gastro‑oesophageal cancers, with several abstracts signalling meaningful shifts in practice.
Breast cancer highlights:
- Next‑generation ADCs in HR‑positive disease showing early efficacy
- CDK4/6 inhibitor re‑challenge vs switch strategies in endocrine‑resistant disease
- HER2‑positive de‑escalation with sustained long‑term outcomes
- ctDNA‑guided adjuvant therapy for MRD‑driven personalisation
- Peri‑operative immunotherapy in TNBC with encouraging survival updates
- Real‑world toxicity and QoL insights from large‑scale datasets
Gastro‑oesophageal cancer highlights:
- Peri‑operative IO + chemotherapy with practice‑changing Phase III data
- HER2‑targeted therapy beyond progression using dual blockade
- Biomarker‑driven first‑line sequencing integrating CLDN18.2, HER2, PD‑L1
- ctDNA for MRD detection guiding adjuvant decisions
- IO + anti‑angiogenic combinations with promising signals
- Enhanced recovery after oesophagectomy from multicentre real‑world data.”